Biotech Industry Stock Update: Cell Therapeutics, Sarepta Therapeutics, ACADIA
Pharma, and Medivation
LONDON, January 2, 2014
LONDON, January 2, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Tuesday, December 31, 2013, the U.S. equity market ended on a positive note
with the S&P 500 ending the day at1,848.36, up 0.40%; the Dow Jones
Industrial Average closing at 16,576.66, up 0.44%; and the NASDAQ Composite
finishing at4,176.59, up 0.54%. The S&P 500 Health Care Sector Index edged
0.06% lower to end the day at 642.30; and the S&P 500 Biotechnology Industry
Index ended the day at 2,802.96, down 0.23%. However, the S&P 500
Biotechnology Industry Index has advanced 0.56% in the last one month and
8.33% in the previous three months, compared to a gain of 2.36% and 9.05% in
the S&P 500 during the respective periods. The major movers in the
Biotechnology Industry included Cell Therapeutics Inc. (NASDAQ: CTIC), Sarepta
Therapeutics Inc. (NASDAQ: SRPT), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD),
and Medivation Inc. (NASDAQ: MDVN). All these companies are tracked by
AAAResearchReports.com. Download free technical analysis and charting reports
on CTIC, SRPT, ACAD, and MDVN now at:
On Tuesday, Cell Therapeutics Inc.'s stock edged lower to end the day at
$1.91, down 0.52% from the previous day's closing price of $1.92. The
company's shares fluctuated between $1.89 and $1.95 during the trading
session. A total of 1.64 million shares were traded, which is below the daily
average volume of 2.88 million. Despite Tuesday's losses, the company's shares
have gained 0.53% in the previous three trading sessions and 15.06% in the
last three months, outperforming the S&P 500, which has gained 0.34% and 9.05%
during the respective periods. Moreover, Cell Therapeutics Inc.'s stock is
trading above its 50-day and 200-day moving averages of $1.83 and $1.37,
respectively. Download free research on CTIC today by registering at:
Shares in Sarepta Therapeutics Inc. traded between $20.23 and $21.06 before
finishing Tuesday's session 1.97% lower at $20.37. A total of 1.55 million
shares were traded, which is below the daily average volume of 2.80 million.
Despite Tuesday's pullback, the company's shares have gained 1.85% in the
previous three trading sessions and 9.28% in the last one month, outperforming
the S&P 500, which has advanced 0.34% and 2.36% during the respective periods.
However, Sarepta Therapeutics Inc.'s stock is trading below its 50-day and
200-day moving averages of $24.67 and $34.66, respectively. Sign up and have
access to our free report on SRPT at:
On Tuesday, shares in ACADIA Pharmaceuticals Inc. closed the day at $24.99,
which is 1.54% lower than the previous day's closing price of $25.38. The
company's shares vacillated between $24.25 and $25.29 during the trading
session. A total of 2.19 million shares were traded, which is below the daily
average volume of 2.37 million. Despite Tuesday's losses, the company's shares
have gained 7.30% in the last one month, outperforming the S&P 500, which has
advanced 2.36%, during the same period. Additionally, ACADIA Pharmaceuticals
Inc.'s stock is trading above its 200-day moving average of $18.95. Sign up
and read the complimentary report on ACAD at:
Medivation Inc.'s stock edged 0.13% higher on Tuesday, ending the day at
$63.82. The company's shares oscillated between $63.33 and $64.98 during the
trading session. A total of 0.47 million shares were traded, which is above
the daily average volume of 1.30 million. The company's shares have gained
1.29% in the last one month and 6.31% in the previous three months, compared
to a gain of 2.36% and 9.05% in the S&P 500 during the respective periods.
Furthermore, Medivation Inc.'s stock is trading above its 50-day and 200-day
moving averages of $62.19 and $55.50, respectively. The free report on MDVN
can be downloaded by signing up now at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID:
Press spacebar to pause and continue. Press esc to stop.